New data shows how the system addresses hyperglycemia and nighttime burden to tackle the unique burdens and challenges of diabetes. Those include managing highs and meal-time management or carb-counting. The company said its latest data also mirrors outcomes across a wide-ranging patient population.
The medtech giant presented its data at the American Diabetes Association Scientific Sessions in Orlando, Florida.
Medtronic wanted to take on hyperglycemia, or high blood sugar, a significant unmet need, according to a news release. Hyperglycemia can lead to serious health problems, including adverse effects on memory, IQ, executive function and learning in children.
The company looked at diabetes burdens such as peak levels at certain times in the day and sleep interruptions during the night.
Medtronic says MiniMed 780G reduces numerous burdens
According to Medtronic, one cause of hyperglycemia comes in the form of the dawn phenomenon, an increase in glucose levels in the early morning. Using a retrospective analysis of real-world data from 6,026 patients, investigators demonstrated that those who upgraded from MiniMed 770G to MiniMed 780G nearly had that morning peak eliminated.
The data looked at the elevation of sensor glucose levels greater than 20 mg/dL from 3 a.m. to 6 a.m. compared to 12 a.m. to 3 a.m. at least 30% of the nights. Switching to 780G decreased dawn phenomenon rates from 12.2% to 4.5%. Time in range also increased from 87.7% to 91.4% from 12 a.m. to 6 a.m., falling in line with dawn phenomenon trends.
“For those living with type 1 diabetes, dawn phenomenon can be a stressful occurrence that feels out of one’s control,” said Dr. Robert Vigersky, chief medical officer, Medtronic Diabetes. “The introduction of the MiniMed 780G system has made it easier to maintain target glucose range with less effort to protect against hyperglycemia. It’s been an absolute gift for my patients who have struggled with stubborn highs throughout their diabetes journey.”
Additionally, Medtronic had real-world data from 8,019 patients younger than seven years old previously on 770G with more than 14 nights on both systems. Data demonstrated that users had fewer overnight sleep interruptions and time in range improvements with 780G’s automatic adjustments. Those adjustments of insulin and glucose corrections came every five minutes, including during sleep.
MiniMed 780G decreased nighttime alarms by 45% for all users and 55% for those who used recommended optimal settings. Uninterrupted sleep increased by 30 minutes and 36 minutes for those groups, respectively.
MiniMed also produces promising data with next-generation sensor
Medtronic also plans to present data on the next iteration of its MiniMed 780G, which pairs with the next-generation Simplera Sync. Simplera Sync, a disposable, all-in-one continuous glucose monitor, requires no overatpe. While still investigational as a combination in the U.S., the system garnered CE mark with the next-generation sensor in January.
A 24-site, single-arm study looked at the pairing and produced “promising” results across all clinical outcome metrics. That includes time in range, time in tight range and time above range. The study compared the system to the run-in group, which used hybrid closed-loop (auto basal only) or open-loop delivery. It also included the use of recommended settings related to the outcome metrics.
“The MiniMed 780G system has firmly established itself as a proven automated insulin delivery system,” said study investigator Dr. Gregory Forlenza, professor and pediatric endocrinologist at the Barbara Davis Center. “With the next iteration of the system and this next-generation Simplera Sync™ sensor, the overall experience for people living with type 1 diabetes could be enhanced and may prove to be a compelling option for diabetes management — particularly when leveraged in combination with recommended optimal settings.”
